2019
1127P Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs
Yu J, Tsay C, Sasaki C, Son Y, Decker R, Mehra S, Burtness B. 1127P Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs. Annals Of Oncology 2019, 30: v457. DOI: 10.1093/annonc/mdz252.019.Peer-Reviewed Original ResearchNon-cancer mortalityExternal beam radiationOverall survivalCancer mortalityOral cavityOropharyngeal squamous cell cancerBrachytherapy-treated patientsGenentech/RocheImpact of brachytherapyReceipt of brachytherapySecond primary cancerEffect of comorbiditySquamous cell cancerProportional hazards regressionSingle-institution studyHigher cancer mortalityBeam radiationElectronic medical recordsGlaxo Smith KlineBristol-Myers SquibbEligible patientsOropharynx SCCHPV statusPrimary malignancySecondary outcomes
2012
The relations between age and androgen deprivation therapy use among men receiving radiation therapy for prostate cancer in the Medicare population.
Quon J, Yu J, Soulos P, Gross C. The relations between age and androgen deprivation therapy use among men receiving radiation therapy for prostate cancer in the Medicare population. Journal Of Clinical Oncology 2012, 30: e15150-e15150. DOI: 10.1200/jco.2012.30.15_suppl.e15150.Peer-Reviewed Original ResearchHigh-risk groupShort life expectancyRisk groupsProstate cancerLife expectancyNational Comprehensive Cancer Network guidelinesAndrogen deprivation therapy useConcurrent androgen deprivation therapyEnd Results-Medicare databaseAndrogen deprivation therapyLow-risk cancersExternal beam radiationLow-risk groupLonger life expectancyDeprivation therapyNCCN guidelinesOlder patientsClinical factorsTherapy useGuideline recommendationsTumor characteristicsNetwork guidelinesCancer characteristicsRadiation therapyMedicare population